Triple Frontiers
Retrospective · Markets

Novo v Lilly: how the weight-loss drug race turned, from profit warnings to pills

Novo Nordisk cut its forecasts, replaced its chief executive and shed 9,000 jobs as Eli Lilly became the first drugmaker worth $1 trillion. A US pricing deal, generic semaglutide in India and new daily pills followed, and by November 2026 Novo had raised its outlook on oral Wegovy sales.

RetrospectiveEvents of 29 July 2025. Published by Triple Frontiers on 18 November 2026 as part of our archive covering events before our launch, based on the sources listed below.
Modern office building of Novo Nordisk's headquarters in Bagsvaerd, Denmark
Novo Nordisk's headquarters in Bagsvaerd, Denmark (file photo, 2016)Photo: News Øresund - Johan Wessman / Wikimedia Commons (CC BY 3.0)

On 29 July 2025 Novo Nordisk, the Danish maker of Wegovy, cut its 2025 sales growth outlook to 8%-14% from 13%-21% and named Mike Doustdar as its new chief executive 1. Investors wiped about $70 billion off its market value that day, according to Reuters 1. Four months later, on 21 November 2025, its American rival Eli Lilly became the first drugmaker to reach a $1 trillion market value 23.

Both make GLP-1 drugs used to treat obesity and type 2 diabetes: Novo sells semaglutide as Wegovy and Ozempic, while Lilly sells tirzepatide as Zepbound and Mounjaro 23. By October 2026 Lilly held 63% of US obesity and diabetes drug sales against Novo’s 36.6%, CNBC reported 4.

Compounded copies and a profit warning

On 21 February 2025 the US Food and Drug Administration said the shortage of semaglutide injections, which began in 2022, was resolved 5. It gave state-licensed pharmacies until 22 April 2025 and outsourcing facilities until 22 May 2025 before it would act against compounded products that were essentially copies of approved semaglutide 5.

Copies stayed on the market. When Novo issued its July profit warning it said more than one million US patients were still using compounded GLP-1 drugs, according to its chief financial officer as cited by Reuters 1. Reuters also reported that weekly prescriptions of Lilly’s Zepbound had overtaken Wegovy’s by more than 100,000 1.

Novo’s shares fell nearly 30% at one point on 29 July before trading more than 20% lower, leaving them down 44% for the year 1. At its June 2024 peak the company had been worth as much as $615 billion, Reuters reported 1. “The magnitude of the guidance cut is a shocker,” said Markus Manns, a portfolio manager at Union Investment 1.

A new chief executive and 9,000 job cuts

Novo had removed its previous chief executive, Lars Fruergaard Jorgensen, in May 2025 1. Doustdar, who has worked at the company since 1992, took over on 7 August 1. “We need to increase the sense of urgency and execute differently,” he told investors 1.

On 10 September 2025 Novo said it would cut 9,000 jobs, a little over 11% of its global workforce, about 5,000 of them in Denmark 6. It put one-off restructuring costs at about $1.3 billion and expected annual savings of the same amount by the end of 2026, pharmaphorum reported 6. It also cut its 2025 operating profit growth projection to 4%-10% from 10%-16% 6. “We need a shift in our mindset and approach so we can be faster and more agile,” Doustdar said 6.

A pricing deal with the White House

On 6 November 2025 both companies agreed a deal with the Trump administration in the Oval Office 78. Medicare and Medicaid would pay about $245 a month for Ozempic, Wegovy, Mounjaro and Zepbound, with a $50 copay for qualifying Medicare patients 78. Officials said cash prices on a new TrumpRx website would average about $350 a month at first and fall to $245 over two years 8. Starting doses of the pill versions, if approved, would cost $149 a month 78.

CBS News reported that about 10% of Medicare patients were expected to qualify, and that prices at the time could reach $1,350 a month 7. Lilly said Zepbound starter doses would cost $299 a month, while Novo declined to give pricing details, the AP reported 8. Trump said the deal “will save lives, improve the health of millions and millions of Americans” 8.

Lilly’s trillion-dollar valuation

Lilly’s shares had risen more than 35% in 2025 when it crossed $1 trillion, Reuters reported 2. Its obesity and diabetes drugs generated more than $10.09 billion of its $17.6 billion revenue in the previous quarter, and tirzepatide had overtaken Merck’s Keytruda as the world’s best-selling drug, according to Reuters 23. The company traded at about 50 times its expected earnings for the next 12 months, according to LSEG data cited by Reuters 2. “It also suggests that investors prefer Lilly over Novo in the obesity arms race,” said Evan Seigerman of BMO Capital Markets 2.

How it unfolded

  1. FDA declares semaglutide shortage resolved, setting deadlines for compounded copies

  2. Key moment. Novo cuts 2025 outlook and names Mike Doustdar chief executive; about $70bn wiped off its value

  3. Key moment. Novo announces 9,000 job cuts

  4. Key moment. Lilly and Novo sign pricing deal with the Trump administration

  5. Key moment. Lilly reaches $1 trillion market value

  6. FDA approves Novo’s oral Wegovy pill

  7. Novo forecasts 2026 sales fall of 5% to 13%

  8. Indian drugmakers announce generic semaglutide

  9. Key moment. FDA approves Lilly’s Foundayo pill

  10. Lilly raises 2026 revenue forecast to $91bn-$92bn

  11. Novo raises 2026 outlook for the third time on Wegovy pill sales

Pills, patents and price cuts

The FDA approved Novo’s oral Wegovy pill in December 2025 9. In a 64-week trial, participants who completed treatment lost an average of 16.6% of their body weight, ABC News reported 9. The US launch began on 5 January 2026 10.

On 4 February 2026 Novo reported 2025 sales of 309.1 billion Danish kroner, up 10% at constant exchange rates, with Wegovy sales up 41% to 79.1 billion kroner 10. It forecast that 2026 sales would fall by 5% to 13%, citing competition, US pricing pressure and semaglutide patent expiries in India, Canada, China and Brazil, BioPharma Dive reported 10. Its shares fell by double digits, erasing nearly $50 billion in value, while Lilly forecast 2026 revenue growth of 23% to 27% 10.

On 24 February 2026 Novo said it would lower the US list price of Wegovy, Ozempic and Rybelsus to $675 a month from 1 January 2027 11. That is a cut of about 50% for Wegovy and about 35% for Ozempic, the company said, and self-pay prices are not affected 11.

In India, Reuters reported that the semaglutide patent expired in March 2026 12. On 21 March Sun Pharma, Dr Reddy’s, Glenmark and Zydus announced generic versions, according to PTI 13. Sun priced its weight-management brand at about Rs 900 to Rs 2,000 a week, and Dr Reddy’s priced its diabetes brand at Rs 4,200 a month 13. Dr Reddy’s co-chairman G V Prasad told Reuters in February that “everybody is going to launch, so we’ll have to figure out who will get market share” 12.

On 1 April 2026 the FDA approved Lilly’s orforglipron pill, sold as Foundayo, after a 50-day review, the AP reported 14. At the top dose, trial participants lost an average of 11.2% of body weight over more than 16 months, against 2.1% on placebo 14. Unlike the Wegovy pill, which must be taken on an empty stomach, Foundayo has no food or water restrictions, according to the AP 14. Its cash price ranges from $149 to $349 a month 14.

Latest status

On 29 October 2026 Lilly reported third-quarter revenue of $24.40 billion and raised its 2026 revenue forecast to $91 billion-$92 billion from $85 billion-$87 billion, CNBC reported 4. Mounjaro revenue rose 65% to $10.72 billion and Zepbound revenue rose 49% to $5.35 billion 4. Foundayo sales were $184 million, below the roughly $229 million analysts expected 4. CNBC said Medicare began covering GLP-1s for weight loss in July 2026 under a temporary pilot programme 4.

On 4 November 2026 Novo raised its 2026 adjusted sales and operating profit guidance to between a 2% fall and a 2% rise at constant exchange rates, from a decline of 0% to 6% 1516. Reuters said it was the third raise of the year 15. Wegovy pill sales reached 5.39 billion Danish crowns in the third quarter, up 53% on the previous quarter, while US sales of injectable Wegovy fell 13% at constant exchange rates 15. “Growth was led by our obesity portfolio, with continued uptake of Wegovy pill in the US,” Doustdar said 15. Novo expects to launch its next obesity drug, CagriSema, in the US in early 2027, pending an FDA decision 16.

Why it matters

Within two years Lilly’s tirzepatide overtook Novo’s semaglutide in US prescriptions, and the gap shows in the two companies’ market values and forecasts 124. Lower US prices, generic semaglutide in India and the move to daily pills are changing how both companies earn money from these drugs 10111315. Novo’s 2027 list-price cuts and its CagriSema launch are the next tests of whether it can narrow the gap 1116.

Sources and references

  1. ArticleReuters via Yahoo Finance, “Wegovy maker Novo’s profit warning triggers $70 billion share rout”, 29 July 2025. Link
  2. ArticleReuters via Tuoi Tre News, “Lilly becomes first drugmaker to hit $1 trillion valuation on weight-loss demand”, 22 November 2025. Link
  3. ArticleManufacturing Chemist, “Eli Lilly becomes first $1 trillion pharma company”, 25 November 2025. Link
  4. ArticleCNBC, “Eli Lilly Q3 2026 earnings”, 29 October 2026. Link
  5. Official documentUS Food and Drug Administration, “FDA Determines Semaglutide Shortage is Resolved”, 21 February 2025. Link
  6. Articlepharmaphorum, “New CEO to slash 9,000 jobs at Novo Nordisk in restructure”, 10 September 2025. Link
  7. ArticleCBS News, “Trump deal to lower weight-loss drug prices in some cases”, 6 November 2025. Link
  8. ArticleAssociated Press via WOWT, “Trump unveils deal to expand coverage and lower costs on obesity drugs”, 6 November 2025. Link
  9. ArticleABC News / Good Morning America, “FDA approves Wegovy pill for weight loss”, 23 December 2025. Link
  10. ArticleBioPharma Dive, “Novo shares tumble by double digits on grim sales outlook”, 4 February 2026. Link
  11. Official documentNovo Nordisk (press release via BioSpace), “Novo Nordisk announces significant reduction in US list price for Wegovy, Ozempic and Rybelsus”, 24 February 2026. Link
  12. ArticleReuters via 97.9 WEVE, “Dr Reddy’s says Wegovy copycat to be priced competitively, with 50-60% discounts feasible”, 17 February 2026. Link
  13. ArticlePTI via Outlook Business, “Sun Pharma, Dr Reddy’s, Glenmark launch generic semaglutide injection in India”, 21 March 2026. Link
  14. ArticleAssociated Press via ABC7, “FDA grants speedy approval to Eli Lilly’s weight-loss pill for obesity”, 1 April 2026. Link
  15. ArticleReuters via TimesLIVE, “Novo Nordisk lifts 2026 outlook as Wegovy pill surges”, 4 November 2026. Link
  16. Articlepharmaphorum, “Oral Wegovy bolsters Novo in Q3”, 4 November 2026. Link

Sources and references are provided for transparency and further reading. Allegations and claims are attributed to their respective sources. Triple Frontiers distinguishes reported allegations from independently established facts.

Spotted an error? Request a correction · Corrections policy

Share this story

Novo v Lilly: how the weight-loss drug race turned, from profit warnings to pills

Newsroom desk Business Desk

Markets, trade and the economics that shape the world. Stories are researched from official records, court documents, institutional reports and published journalism, with the help of AI research tools, and edited for Triple Frontiers. Every factual claim is linked to its source.

Newsletter

The Frontier Brief

The week’s essential international reporting and new investigations, every Friday.